The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Clinical uses of intravenous immunoglobulin
Open accessAbstract
Intravenous immunoglobulin (IVIG) is a blood product prepared from the serum of between 1000 and 15 000 donors per batch. It is the treatment of choice for patients with antibody deficiencies. For this indication, IVIG is used at a ‘replacement dose’ of 200–400 mg/kg body weight, given approximately 3-weekly. In contrast, ‘high dose’ IVIG (hdIVIG), given most frequently at 2 g/kg/month, is used as an ‘immunomodulatory’ agent in an increasing number of immune and inflammatory disorders. Initial use of hdIVIG was for immune thrombocytopenic purpura (ITP) in children [1]. The clinical specialities using the largest amounts of IVIG are neurology, haematology, immunology, nephrology, rheumatology and dermatology. IVIG has had a major impact on the treatment of neurological disorders including dermatomyositis, Guillain–Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), myasthenia gravis and stiff person syndrome. In haematology it is used to treat immune cytopenias, parvovirus B19 associated red cell aplasia, hypogammaglobulinaemia secondary to myeloma and chronic lymphatic leukaemia and post-bone marrow transplantation. In immunology IVIG is used in the treatment of primary antibody deficiency (PAD), in nephrology, rheumatology and ophthalmology it has been used to treat vasculitis, systemic lupus erythematosis (SLE), mucous membrane pemphigoid and uveitis and in dermatology it is used most commonly to treat Kawasaki syndrome, dermatomyositis, toxic epidermal necrolysis and the blistering diseases (Table 1). Major uses of intravenous imunoglobulin (IVIG). IVIG is used mainly at high dose (2 g/kg) for the indications listed in neurology, haematology, rheumatology, dermatology and others while in immunology replacement doses (0·4 g/kg) are given. The uses listed are not exhaustive, but aim to cover the disorders for which IVIG is most frequently used and whether a randomized controlled (RCT) study or Cochrane review (CR) is available. CVID, common variable immunodeficiency; XLA, X-linked agammaglobulinaemia; HIGM, hyper-IgM syndrome; WAS, Wiskott Aldrich syndrome; CLL, chronic lymphocytic leukaemia. *Blistering diseases include pemphigus vulgaris, pemphigus folaceous, bullous and nodular pemphigoid, mucous membrane pemphigoid, gestational pemphigoid, epidermolysis bullosa acquisita and linear IgA disease. Major uses of intravenous imunoglobulin (IVIG). IVIG is used mainly at high dose (2 g/kg) for the indications listed in neurology, haematology, rheumatology, dermatology and others while in immunology replacement doses (0·4 g/kg) are given. The uses listed are not exhaustive, but aim to cover the disorders for which IVIG is most frequently used and whether a randomized controlled (RCT) study or Cochrane review (CR) is available. CVID, common variable immunodeficiency; XLA, X-linked agammaglobulinaemia; HIGM, hyper-IgM syndrome; WAS, Wiskott Aldrich syndrome; CLL, chronic lymphocytic leukaemia. *Blistering diseases include pemphigus vulgaris, pemphigus folaceous, bullous and nodular pemphigoid, mucous membrane pemphigoid, gestational pemphigoid, epidermolysis bullosa acquisita and linear IgA disease. In this paper, we review recent developments in the understanding of mechanisms of action of IVIG, the major current clinical areas of use concentrating on conditions with a better established evidence base and discuss emerging areas of use of IVIG. The mechanisms of action of therapeutic immunoglobulin are complex, but over recent years important advances in understanding have been made (summarized in Fig. 1) [2]; the predominant mechanism operating in a particular situation appears to depend on both the immunoglobulin dose and the pathogenesis of the disease under consideration. Immunomodulatory actions of intravenous immunoglobulin. Intravenous immunoglobulin (IVIG), may for the purposes of understanding, be thought of as four separate components: (1) actions mediated by the variable regions F(ab′)2, (2) actions of Fc region on a range of Fc receptors (FcR), (3) actions mediated by complement binding within the Fc fragment and (4) immunomodulatory substances other than antibody in the IVIG preparations. It should be remembered that not all the potential mechanisms of action fit perfectly into the groupings and that several mechanisms may act concurrently (TCR, T cell receptor; ADCC, antibody dependent cellular cytotoxicity; DC, dendritic cell). Commercial IVIG preparations contain a ‘species repertoire’ of antibody specificities, resulting in neutralization of a wide range of antigens including pathogens and superantigens [3]; there is, however, significant batch-to-batch variation in the concentration of a particular antibody [4]. IVIG has been shown to have a considerable inhibitory effect on mitogen-induced T cell proliferation in vitro[5]. This effect has been shown for intact IgG, with less evidence for a role for Fc fragment [6]. Both antigen-dependent
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD
Imbach, P., d'APUZZO, V., Hirt, A., Rossi, E., Vest, M., Barandun, S., Baumgartner, C., Morell, A., Schöni, M., & Wagner, H. P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92400-4 · Cited by 1,666
A New Infantile Acute Febrile Mucocutaneous Lymph Node Syndrome (MLNS) Prevailing in Japan
Kawasaki, T., Kosaki, F., Okawa, S., Shigematsu, I., & Yanagawa, H. (1974) · Pediatrics · doi:10.1542/peds.54.3.271 · Cited by 1,508
The Treatment of Kawasaki Syndrome with Intravenous Gamma Globulin
Newburger, J. W., Takahashi, M., Burns, J. C., Beiser, A. S., Chung, K. J., Duffy, C. E., Glode, M. P., Mason, W. H., Reddy, V., Sanders, S. P., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198608073150601 · Cited by 1,419
Kawasaki, T. (1967) · PubMed · Cited by 1,359
Newburger, J. W., Takahashi, M., Beiser, A. S., Burns, J. C., Bastian, J., Chung, K. J., Colan, S. D., Duffy, C. E., Fulton, D. R., Glode, M. P., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106063242305 · Cited by 1,220
Kato, H., & Takahashi, Y. (1995) · Cited by 1,186
Dalakas, M. C., Illa, I., Dambrosia, J. M., Soueidan, S. A., Stein, D. P., Otero, C., Dinsmore, S. T., & McCrosky, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292704 · Cited by 1,136
Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005
Kennedy, C. O. (1971) · British Homeopathic Journal · doi:10.1016/s0007-0785(71)80027-3 · Cited by 974
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
Intravenous immunoglobulin for Guillain-Barré syndrome
Hughes, R. A., Swan, A. V., & van Doorn, P. A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002063.pub6 · Cited by 721
Fehr, J., Hofmann, V., & Rappeler, U. (1982) · New England Journal of Medicine · doi:10.1056/nejm198205273062102 · Cited by 708
Hughes, R., Bensa, S., Willison, H., Van Den Bergh, P., Comi, G., Illa, I., Nobile‐Orazio, E., Van Doorn, P., Dalakas, M., Bojar, M., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1088 · Cited by 628
Kaul, R., McGeer, A., Norrby‐Teglund, A., Kotb, M., Schwartz, B., O'Rourke, K., Talbot, J., Low, D. E., & The Canadian Streptococcal Study Group (1999) · Clinical Infectious Diseases · doi:10.1086/515199 · Cited by 544
Acquired Haemophilia: Review and Meta‐Analysis Focused on Therapy and Prognostic Factors
Delgado, J., Jimenez‐Yuste, V., Hernandez‐Navarro, F., & Villar, A. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04162.x · Cited by 469
High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome
Dalakas, M. C., Fujii, M., Li, M., Lutfi, B., Kyhos, J., & McElroy, B. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa01167 · Cited by 434
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
Gottenberg, J.-E., Guillevin, L., Lambotte, O., Combe, B., Allanore, Y., Cantagrel, A., Larroche, C., Soubrier, M., Bouillet, L., Dougados, M., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.029694 · Cited by 401
Bachot, N., Revuz, J., & Roujeau, J.-C. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.1.33 · Cited by 380
Busse, P. J., Razvi, S., & Cunningham-Rundles, C. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.124999 · Cited by 351
Prins, C., Kerdel, F. A., Padilla, R. S., Hunziker, T., Chimenti, S., Viard, I., Mauri, D. N., Flynn, K., Trent, J., Margolis, D. J., et al. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.1.26 · Cited by 325
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin
Bayry, J., Lacroix-Desmazes, S., Carbonneil, C., Misra, N., Donkova, V., Pashov, A., Chevailler, A., Mouthon, L., Weill, B., Bruneval, P., et al. (2003) · Blood · doi:10.1182/blood-2002-05-1447 · Cited by 306
Bruhns, P., Samuelsson, A., Pollard, J. W., & Ravetch, J. V. (2003) · Immunity · doi:10.1016/s1074-7613(03)00080-3 · Cited by 304
Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura
Bussel, J., Kimberly, R. P., Inman, R., Schulman, I., Cunningham‐Rundles, C., Cheung, N. K., Smithwick, E., O'Malley, J., Barandun, S., & Hilgartner, M. W. (1983) · Blood · doi:10.1182/blood.v62.2.480.480 · Cited by 301
Treatment of systemic vasculitis with pooled intravenous immunoglobulin
Jayne, D. R. W., Lockwood, C. M., Davies, M. J., Fox, C. J. V., & Black, C. M. (1991) · The Lancet · doi:10.1016/0140-6736(91)92797-6 · Cited by 297
Takei, S., Arora, Y. K., & Walker, S. M. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116240 · Cited by 292
Roifman, C., Levison, H., & Gelfand, E. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90494-6 · Cited by 291
Intravenous immunoglobulin in autoimmune chronic urticaria
O’Donnell, Barr, Black, K., Francis, Kermani, Niimi, Barlow, Winkelmann, & Greaves (1998) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1998.02033.x · Cited by 287
Prasad, N. K. A., Papoff, G., Zeuner, A., Bonnin, E., Kazatchkine, M. D., Ruberti, G., & Kaveri, S. V. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3781 · Cited by 279
Multifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebo-controlled study
Federico, P., Zochodne, D. W., Hahn, A. F., Brown, W. F., & Feasby, T. E. (2000) · Neurology · doi:10.1212/wnl.55.9.1256 · Cited by 263
Bain, P. G., Motomura, M., Newsom-Davis, J., Misbah, S. A., Chapel, H. M., Lee, M. L., Vincent, A., & Lang, B. (1996) · Neurology · doi:10.1212/wnl.47.3.678 · Cited by 261
Self-citationChapel, H. M., Lee, M., Hargreaves, R., Pamphilon, D. H., Prentice, A. G., Chapel, H. M., Hargreaves, R., Lee, M., Pamphilon, D. H., & Prentice, A. G. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90180-5 · Cited by 260
Eijkhout, H. W., van der Meer, J. W. M., Kallenberg, C. G. M., Weening, R. S., van Dissel, J. T., Sanders, L. A. M., Strengers, P. F. W., Nienhuis, H., Schellekens, P. T. A., & for the Inter-University Working Party for the Study of Immune Deficiencies (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-3-200108070-00008 · Cited by 238
Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants
Ohlsson, A., & Lacy, J. B. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000361.pub3 · Cited by 234
Hughes, R. A., Raphael, J., Swan, A. V., et al. (2001) · Research Portal (King's College London) · Cited by 221
Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic Leukemia
Weeks, J. C., Tierney, M. R., & Weinstein, M. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107113250202 · Cited by 204
Pulmonary abnormalities in patients with primary hypogammaglobulinemia☆☆☆★
Kainulainen, L., Varpula, M., Liippo, K., Svedström, E., Nikoskelainen, J., & Ruuskanen, O. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70085-0 · Cited by 193
Aukrust, P., Froland, S., Liabakk, N., Muller, F., Nordoy, I., Haug, C., & Espevik, T. (1994) · Blood · doi:10.1182/blood.v84.7.2136.2136 · Cited by 191
A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response
Levy, Y., Sherer, Y., Ahmed, A., Langevitz, P., George, J., Fabbrizzi, F., Terryberry, J., Meissner, M., Lorber, M., Peter, J. B., et al. (1999) · Lupus · doi:10.1191/096120399678841007 · Cited by 191
Pierce, L. R., & Jain, N. (2003) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(03)00038-5 · Cited by 185
Norrby-Teglund, A., Kaul, R., Low, D. E., McGeer, A., Newton, D. W., Andersson, J., Andersson, U., & Kotb, M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.8.3057 · Cited by 182
Hommes, O. R., Sørensen, P. S., Fazekas, F., Enriquez, M. M., Koelmel, H. W., Fernandez, O., Pozzilli, C., & O'Connor, P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17101-8 · Cited by 182
Efficacy of Intravenous Immunoglobulin in Primary Humoral Immunodeficiency Disease
CUNNINGHAM-RUNDLES, C., SIEGAL, F. P., SMITHWICK, E. M., LION-BOULÉ, A., CUNNINGHAM-RUNDLES, S., O'MALLEY, J., BARANDUN, S., & GOOD, R. A. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-4-435 · Cited by 180
Immunomodulatory action of intravenous immunoglobulin
Sewell, W. A. C., & Jolles, S. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01545.x · Cited by 171
Self-citationIntravenous immunoglobulin for suspected or subsequently proven infection in neonates
Ohlsson, A., & Lacy, J. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001239.pub2 · Cited by 163
Trautmann, A., Akdis, M., Schmid-Grendelmeier, P., Disch, R., Bröcker, E.-B., Blaser, K., & Akdis, C. A. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118796 · Cited by 162
Pooled Human IgG Modulates Cytokine Production in Lymphocytes and Monocytes
Andersson, U., Björk, L., Skansén‐Saphir, U., & Andersson, J. (1994) · Immunological Reviews · doi:10.1111/j.1600-065x.1994.tb00855.x · Cited by 162
Abe, Y., Horiuchi, A., Miyake, M., & Kimura, S. (1994) · Immunological Reviews · doi:10.1111/j.1600-065x.1994.tb00854.x · Cited by 161
Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG.
Andersson, J., Björk, L., Skansén-Saphir, U., et al. (1993) · PubMed · Cited by 146
Ammann, A. J., Ashman, R. F., Buckley, R. H., Hardie, W. R., Krantman, H. J., Nelson, J. W., Ochs, H. D., Stiehm, E. R., Tiller, T., Wara, D. W., et al. (1982) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(82)90022-8 · Cited by 139
Prophylactic antibiotics for the prevention of early infection in multiple myeloma
Oken, M. M., Pomeroy, C., Weisdorf, D. J., & Bennett, J. M. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00043-7 · Cited by 128
Vassilev, T. L., Gélin, C., Kaveri, S. V., Zilber, M., Boumsell, L., & Kazatchkine, M. D. (1993) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1993.tb03407.x · Cited by 120
Sørensen, P. S., Fazekas, F., & Lee, M. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.2002.00501.x · Cited by 119
de Souza, V. R., Carreno, M., Kaveri, S. V., Ledur, A., Sadeghi, H. M., Cavaillon, J., Kazatchkine, M. D., & Haeffner‐Cavaillon, N. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250521 · Cited by 118
Vassilev, T. L., Kazatchkine, M. D., Huyen, J. D. V., Mekrache, M., Bonnin, E., Mani, J. C., Lecroubier, C., Korinth, D., Baruch, D., Schriever, F., et al. (1999) · Blood · doi:10.1182/blood.v93.11.3624 · Cited by 116
Natural antibodies sustain differentiation and maturation of human dendritic cells
Bayry, J., Lacroix‐Desmazes, S., Donkova-Petrini, V., Carbonneil, C., Misra, N., Lepelletier, Y., Delignat, S., Varambally, S., Oksenhendler, É., Lévy, Y., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402183101 · Cited by 104
Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants
Ohlsson, A., & Lacy, J. B. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000361.pub2 · Cited by 98
Polyvalent immunoglobulin for intravenous use interferes with cell proliferationin vitro
van Schaik, I. N., Lundkvist, I., Vermeulen, M., & Brand, A. (1992) · Journal of Clinical Immunology · doi:10.1007/bf00920789 · Cited by 81
Aghamohammadi, A., Moin, M., Farhoudi, A., Rezaei, N., Pourpak, Z., Movahedi, M., Gharagozlou, M., Nabavi, M., & Shahrokhi, A. (2003) · FEMS Immunology & Medical Microbiology · doi:10.1016/s0928-8244(03)00304-3 · Cited by 77
Efficacy of human intravenous immune globulin in pyoderma gangrenosum
Gupta, A. K., Shear, N. H., & Sauder, D. N. (1995) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(95)90218-x · Cited by 70
Intravenous immunoglobulin for Guillain-Barré syndrome
Hughes, R. A. C., Raphaël, J. C., Swan, A. V., & van Doorn, P. A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002063.pub2 · Cited by 68
Ericson, S. G., Coleman, K. D., Wardwell, K., Baker, S., Fanger, M. W., Guyre, P. M., & Ely, P. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.393931.x · Cited by 57
Jolles, S. R. A., Sewell, C., Webster, D., Ryan, A., Heelan, B. T., Waite, A., & Rustin, M. H. A. (2003) · Acta Dermato Venereologica · doi:10.1080/00015550310020549 · Cited by 50
Self-citationAktaş, O., Waiczies, S., Grieger, U., Wendling, U., Zschenderlein, R., & Zipp, F. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00243-0 · Cited by 41
Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on
Bierling, P., & Godeau, B. (2004) · Vox Sanguinis · doi:10.1111/j.0042-9007.2004.00391.x · Cited by 37
Annular Crystalline Keratopathy in Association With Immunoglobulin Therapy for Pyoderma Gangrenosum
Budde, M., Gusek-Schneider, G. C., Mayer, U., & Seitz, B. (2003) · Cornea · doi:10.1097/00003226-200301000-00021 · Cited by 20
Cited by
A Review of SARS-CoV-2 and the Ongoing Clinical Trials
Tu, Y.-F., Chien, C.-S., Yarmishyn, A. A., Lin, Y.-Y., Luo, Y.-H., Lin, Y.-T., Lai, W.-Y., Yang, D.-M., Chou, S.-J., Yang, Y.-P., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072657 · Cited by 686
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
Hogarth, P. M., & Pietersz, G. A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2909 · Cited by 348
Current status of potential therapeutic candidates for the COVID-19 crisis
Zhang, J., Xie, B., & Hashimoto, K. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.04.046 · Cited by 283
Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action
NEGI, V.-S., ELLURU, S., SIBÉRIL, S., GRAFF-DUBOIS, S., MOUTHON, L., KAZATCHKINE, M. D., LACROIX-DESMAZES, S., BAYRY, J., & KAVERI, S. V. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9088-9 · Cited by 271
Metadata
- Authors
- Jolles, S., Sewell, W. A. C., & Misbah, S. A.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-16
- Volume
- 142
- Issue
- 1
- Pages
- 1-11
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W2104373525
- Cited by
- 374
- References
- 65
- FWCI
- 5.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.